In breast cancer, the presence of CAFs itself does not determine the aggressiveness of tumors, but rather a CD10+GPR77+ subset of CAFs driven by NF-κB signaling plays a key role in promoting tumor formation and chemoresistance [11]. Here, NFKB1 is linked to neoplasm.